Thursday, June 26, 2025 6/26/2025

DEVELOPMENT OF THE HBCAG AS A VACCINE CARRIER PLATFORM

Award Number: R01AI049730
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/30/2000
PERIOD OF PERFORMANCE END DATE: 06/30/2009

Group Awards By:

View Award Description

DEVELOPMENT OF THE HBCAG AS A VACCINE CARRIER PLATFORM - DESCRIPTION (provided by applicant): This application is a competitive continuation of R01 AI49730-03. There are a number of advantages to the use of peptide and small well-defined oligosaccharide (OS) antigens for subunit vaccine design. For example, chemical purity and safety, ease of production, cost, stability and mutability. However, peptidic and OS antigens require conjugation to T cell carrier proteins for efficient delivery to the immune system. The hepatitis core platform is a particulate carrier capable of eliciting high titer antibody responses to weak "hapten-like" peptidic and OS antigens incorporated onto core particles. During the course of this grant we have used the hepatitis B core (HBcAg) as a carrier platform for P. falciparum malaria circumsporozoite (CS) neutralizing repeat sequences (i.e., NANPn). The hybrid HBcAg-CS repeat particles are highly immunogenic in mice and are currently in phase 1/11clinical trials. Although the HBcAg is highly immunogenic, we have identified a number of theoretical and practical limitations to the use of the HBcAg as a vaccine platform. To address these limitations we are developing the core protein from the woodchuck hepadna virus (WHcAg) as a particulate carrier platform for several reasons: (1) The WHcAg is equally or more immunogenic than the HBcAg at the B cell and T cell levels; (2) the use of the WHcAg does not compromise the anti-HBc diagnostic assay because WHcAg and HBcAg are not crossreactive at the antibody level; (3) no pre-existing antibody to the WHcAg is present unlike for the HBcAg; (4) immune tolerance to HBcAg in chronic HBV carriers (300-400 million worldwide) can be circumvented by the use of the WHcAg platform because WHcAg and HBcAg are only partially crossreactive at the CD4+ T cell level; and (5) we have developed a WHcAg-based combinatorial technology that is more versatile than the existing HBcAg technology in terms of accommodating the insertion of a greater variety of foreign epitopes. For example, we have modified the WHcAg gene to create libraries of 17 insertion sites and 22 C-terminal modifications. Combining these libraries has allowed us to successfully insert 22 of 24 attempted foreign epitopes into the WHcAg platform. We propose to continue to expand the WHcAg combinatorial technology and perform biochemical/structural analysis of hybrid-WhcAg particles in an attempt to correlate structure and function (Aim 1); characterize the immune response to hybrid-WHcAg particles in vitro and in vivo in small animal models including challenge experiments to determine the protective efficacy of hybrid-WHcAg vaccine candidates if warranted (Aim 2); and extend the WHcAg platform to accommodate non-linear larger protein and carbohydrate antigens (Aim 3). A number of unique immunologic characteristics of the WHcAg and of the hybrid-WHcAg particles produced to date suggest that this particulate platform will be useful as a means of delivering a variety of medically relevant antigens to the immune system.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2008 ( Subtotal = $531,825 )
2008	2008	VACCINE RESEARCH INSTITUTE OF SAN DIEGO	3030 SCIENCE PARK ROAD	SAN DIEGO	CA	92121	SAN DIEGO	USA	Allergy and Infectious Diseases Research	000	8	7/28/2008	NON-COMPETING CONTINUATION	$531,825
														Subtotal = $531,825

Issue Date FY: 2007 ( Subtotal = $528,945 )
2007	2007	VACCINE RESEARCH INSTITUTE OF SAN DIEGO	3030 SCIENCE PARK ROAD	SAN DIEGO	CA	92121	SAN DIEGO	USA	Allergy and Infectious Diseases Research	000	7	7/20/2007	NON-COMPETING CONTINUATION	$528,945
														Subtotal = $528,945

Issue Date FY: 2006 ( Subtotal = $531,567 )
2006	2006	VACCINE RESEARCH INSTITUTE OF SAN DIEGO	3030 SCIENCE PARK ROAD	SAN DIEGO	CA	92121	SAN DIEGO	USA	Allergy and Infectious Diseases Research	000	6	6/20/2006	NON-COMPETING CONTINUATION	$531,567
														Subtotal = $531,567

Issue Date FY: 2005 ( Subtotal = $531,258 )
2005	2005	VACCINE RESEARCH INSTITUTE OF SAN DIEGO	3030 SCIENCE PARK ROAD	SAN DIEGO	CA	92121	SAN DIEGO	USA	Microbiology and Infectious Diseases Research	000	5	6/29/2005	NON-COMPETING CONTINUATION	$531,258
														Subtotal = $531,258

Issue Date FY: 2004 ( Subtotal = $556,773 )
2004	2004	VACCINE RESEARCH INSTITUTE OF SAN DIEGO	3030 SCIENCE PARK ROAD	SAN DIEGO	CA	92121	SAN DIEGO	USA	Microbiology and Infectious Diseases Research	000	4	6/25/2004	COMPETING CONTINUATION	$556,773
														Subtotal = $556,773

Issue Date FY: 2002 ( Subtotal = $320,000 )
2002	2002	VACCINE RESEARCH INSTITUTE OF SAN DIEGO	3030 SCIENCE PARK ROAD	SAN DIEGO	CA	92121	SAN DIEGO	USA	Microbiology and Infectious Diseases Research	000	3	8/2/2002	NON-COMPETING CONTINUATION	$320,000
														Subtotal = $320,000

Issue Date FY: 2001 ( Subtotal = $320,000 )
2001	2001	VACCINE RESEARCH INSTITUTE OF SAN DIEGO	3030 SCIENCE PARK ROAD	SAN DIEGO	CA	92121	SAN DIEGO	USA	Microbiology and Infectious Diseases Research	000	2	8/2/2001	NON-COMPETING CONTINUATION	$320,000
														Subtotal = $320,000

Issue Date FY: 2000 ( Subtotal = $305,549 )
2000	2000	VACCINE RESEARCH INSTITUTE OF SAN DIEGO	3030 SCIENCE PARK ROAD	SAN DIEGO	CA	92121	SAN DIEGO	USA	Microbiology and Infectious Diseases Research	000	1	9/18/2000	NEW	$305,549
														Subtotal = $305,549

Grand Total All Awards = $3,625,917

Top

All Categories

About

Search

Reports

Data Submission

Award Information

DEVELOPMENT OF THE HBCAG AS A VACCINE CARRIER PLATFORM

Award Number: R01AI049730

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/30/2000

PERIOD OF PERFORMANCE END DATE: 06/30/2009

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer